ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 0367 • ACR Convergence 2021

    Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)

    Marco Garrido-Cumbrera1, Souzi Makri2, Denis Poddubnyy3, Christine Bundy4, Laura Christen5, Sergio Sanz-Gomez6, José Correa-Fernández6, Raj Mahapatra7, Carlos Jesús Delgado-Domínguez6 and Victoria Navarro-Compán8, 1Health & Territory Research (HTR), University of Seville, Sevilla, Spain, 2Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, 3Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 4Cardiff University, Cardiff, Wales, United Kingdom, 5Novartis Pharma AG, Basel, Switzerland, 6Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, 7Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, 8Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

    Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…
  • Abstract Number: 0575 • ACR Convergence 2021

    World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015

    Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France

    Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…
  • Abstract Number: 0910 • ACR Convergence 2021

    The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort

    Jean Liew1, S. Reza Jafarzadeh2, Maureen Dubreuil3, Susan Heckbert4, Stephen Mooney4, Matthew Brown5, Mariko Ishimori6, John Reveille7, Michael Ward8, Michael Weisman9 and Lianne Gensler10, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine/ VA Boston, Boston, MA, 4University of Washington, Seattle, WA, 5King's College London, London, United Kingdom, 6Cedars-Sinai Health System, Los Angeles, CA, 7Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 8Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, 9Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 10Department of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…
  • Abstract Number: 1045 • ACR Convergence 2021

    Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis

    Junming Chen, Xuechan Huang, Qidang Huang, Zhixiang Huang, Yukai Huang, Yuqi Liu, Lixin Huang, Shanmiao Sun, Zhuyi ji and Tianwang Li, Guangdong Second Provincial General Hospital, Guangzhou, China (People's Republic)

    Background/Purpose: To investigate the composition of phospholipid fatty acids in erythrocyte membranes from patients with ankylosing spondylitis (AS), and determine the correlations between the percentage…
  • Abstract Number: 1919 • ACR Convergence 2021

    Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis

    Denis Poddubnyy1, Fabian Proft2, Kay-Geert Hermann2, Laura Spiller2, Stefan Niehues2, Lisa Adams2, Mikhail Protopopov2, Valeria Rios Rodriguez2, Burkhard Muche2, Judith Rademacher2, Murat Torgutalp2, Keno Bressem2 and Janis Vahldiek2, 1Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 2Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many…
  • Abstract Number: 0063 • ACR Convergence 2021

    Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling

    Solveig S. Groen1, Christian S Thudium2, Morten Karsdal3, Anne-Christine Bay-Jensen2 and Signe Holm Nielsen4, 1University of Copenhagen, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, 4Nordic Bioscience and Technical University of Denmark, Biomedicine and Biotechnology, Kgs. Lyngby, Herlev, Denmark

    Background/Purpose: In spondyloarthritis (SpA) Th17 cells play a critical role in activating the pathogenic chain leading to manifestations related to skin, joints and entheses. Elevated…
  • Abstract Number: 0368 • ACR Convergence 2021

    Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study

    Miranda van Lunteren1, Anne Boel1, Clementina López Medina2, Joachim Sieper3, Désirée van der Heijde4 and Floris van Gaalen1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, 3Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

    Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
  • Abstract Number: 0748 • ACR Convergence 2021

    Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia

    Xenofon Baraliakos, Styliani Tsiami, Maria Claudia Gkelaki, Piet Dukatz, Uta Kiltz and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…
  • Abstract Number: 0911 • ACR Convergence 2021

    Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

    Thibaut Delépine1, Peggy PHILIPPE2, Emeline CAILLIAU3, Eric HOUVENAGEL4, Tristan Pascart5, Xavier DEPREZ6, Rene-Marc FLIPO7 and Jean-Guillaume LETAROUILLY2, 1Lille University Hospital, Lille, France, 2Rheumatology Department, University Hospital of Lille, Lille, France, 3Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, 4Rheumatology Department, Lille Catholic Hospitals, Lomme, France, 5Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, 6Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, 7Rheumatology Department, Lille University Hospital, Lille, France

    Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…
  • Abstract Number: 1093 • ACR Convergence 2021

    Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis

    Bindee Kuriya1, Shadi Akhtari2, Mohammad Movahedi3, Jacob Udell4, Patrick Lawler4, Paula Harvey5 and Lihi Eder4, 1University of Toronto - Toronto, Toronto, ON, Canada, 2Women's College Hospital, University of Toronto, North York, ON, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Women's College Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…
  • Abstract Number: 1922 • ACR Convergence 2021

    Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom

    Raj Sengupta1, Shruti Narasimham2, Borja Mato3, Matic Meglic3, Chiara Perella3, Paula Pamies4 and Paul Emery5, 1The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…
  • Abstract Number: 0065 • ACR Convergence 2021

    Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity

    Jiri Baloun1, Kristyna Bubova1, Aneta Pekacova1, Monika Gregova2, Sarka Forejtova1, Jana Horinkova1, Michal Tomcik3, Jindriska Gatterova1, Jiri Vencovsky1, Karel Pavelka3 and Ladislav Senolt3, 1Institute of Rheumatology, Prague, Czech Republic, 2Rheumatology Institute Prague, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…
  • Abstract Number: 0369 • ACR Convergence 2021

    High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland

    Sinead Maguire1, Phil Gallagher2 and Finbar (Barry) O'Shea1, 1St James's Hospital, Dublin, Ireland, 2St Vincent's Hospital, Dublin, Ireland

    Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…
  • Abstract Number: 0820 • ACR Convergence 2021

    The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

    Ulf Müller-Ladner1, Karl Gaffney2, Deepak Jadon3, Ulrich Freudensprung4 and Janet Addison5, 1JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, 2Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, 3Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, 4Biogen International GmbH, Baar, Switzerland, 5Biogen Idec, Maidenhead, United Kingdom

    Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…
  • Abstract Number: 0912 • ACR Convergence 2021

    Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study

    Atul Deodhar1, Shelly Kafka2, Elizabeth Hsia3, Kim Hung Lo4, Kim Lilianne4, Stephen Xu3 and John Reveille5, 1Oregon Health & Science University, Portland, OR, 2Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, 3Janssen Research & Development, LLC, Spring House, PA, 4Department of Biostatics, Janssen Research & Development, LLC, Spring House, Spring House, PA, 5Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: The GO-ALIVE study assessed efficacy and safety of intravenous golimumab (IV GLM) in patients with ankylosing spondylitis (AS).1,2 In this post hoc analysis, we…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology